Genetic predictors of taxane-induced neurotoxicity in a SWOG phase III intergroup adjuvant breast cancer treatment trial (S0221). (Q36495920)

14 August 2017

Genetic predictors of taxane-induced neurotoxicity in a SWOG phase III intergroup adjuvant breast cancer treatment trial (S0221). (English)

1 reference

14 August 2017

phase III clinical trial

0 references

1 reference

1 reference

21

Christine B Ambrosone

1 reference

14 August 2017

9

Dawn L Hershman

1 reference

14 August 2017

13

Claudine Isaacs

1 reference

14 August 2017

Lara E Sucheston

1

1 reference

14 August 2017

Hua Zhao

2

1 reference

14 August 2017

Song Yao

3

1 reference

14 August 2017

Gary Zirpoli

4

1 reference

14 August 2017

Song Liu

5

1 reference

14 August 2017

William E Barlow

6

1 reference

14 August 2017

Halle C F Moore

7

1 reference

14 August 2017

G Thomas Budd

8

1 reference

14 August 2017

Warren Davis

10

1 reference

14 August 2017

Gregory L Ciupak

11

1 reference

14 August 2017

James A Stewart

12

1 reference

14 August 2017

Timothy J Hobday

14

1 reference

14 August 2017

Muhammad Salim

15

1 reference

14 August 2017

Gabriel N Hortobagyi

16

1 reference

14 August 2017

Julie R Gralow

17

1 reference

14 August 2017

Robert B Livingston

18

1 reference

14 August 2017

Kathy S Albain

19

1 reference

14 August 2017

Daniel F Hayes

20

1 reference

14 August 2017

language of work or name

English

0 references

publication date

16 July 2011

1 reference

Breast Cancer Research and Treatment

14 August 2017

1 reference

14 August 2017

130

1 reference

14 August 2017

3

1 reference

14 August 2017

993-1002

1 reference

https://scigraph.springernature.com/pub.10.1007/s10549-011-1671-3

14 August 2017

0 references

cites work

BRCA1 and its toolbox for the maintenance of genome integrity

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3532924

Chromosomal instability determines taxane response

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3532924

Human cancer cells commonly acquire DNA damage during mitotic arrest

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3532924

Taxanes, microtubules and chemoresistant breast cancer.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3532924

Emergence of a DNA-damage response network consisting of Fanconi anaemia and BRCA proteins

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3532924

The Fanconi anemia (FA) pathway confers glioma resistance to DNA alkylating agents

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3532924

Peripheral neuropathy induced by microtubule-stabilizing agents.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3532924

The Fanconi Anemia/BRCA pathway: new faces in the crowd

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3532924

A requirement for breast-cancer-associated gene 1 (BRCA1) in the spindle checkpoint

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3532924

The role of BRCA1 in the cellular response to chemotherapy

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3532924

Tracing the network connecting BRCA and Fanconi anaemia proteins

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3532924

BRCA1 functions as a differential modulator of chemotherapy-induced apoptosis

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3532924

The Fanconi anaemia/BRCA pathway

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3532924

The structure of haplotype blocks in the human genome

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3532924

Inference of population structure using multilocus genotype data

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3532924

Validation and reduction of FACT/GOG-Ntx subscale for platinum/paclitaxel-induced neurologic symptoms: a gynecologic oncology group study.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3532924

Comparison of three methods to estimate genetic ancestry and control for stratification in genetic association studies among admixed populations.

21 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3532924

Reporting recommendations for tumor marker prognostic studies (REMARK).

21 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3532924

TAC--a new standard in adjuvant therapy for breast cancer?

21 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3532924

Adjuvant docetaxel for node-positive breast cancer

21 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3532924

Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: results from NSABP B-28.

21 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3532924

DNA damage induced by paclitaxel and DNA repair capability of peripheral blood lymphocytes as evaluated by the alkaline comet assay

21 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3532924

Histopathology, FIGO stage, and BRCA mutation status of ovarian cancers from the Gilda Radner Familial Ovarian Cancer Registry

21 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3532924

Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer.

21 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3532924

Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients: the FNCLCC PACS 01 Trial

21 September 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/21766209

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1007/S10549-011-1671-3

1 reference

14 August 2017

1 reference

14 August 2017

1 reference